What is Glutathione?
Glutathione (GSH, gamma-L-glutamyl-L-cysteinylglycine) is an endogenous tripeptide composed of three amino acids: glutamic acid, cysteine, and glycine. Present in virtually all eukaryotic cells, it is the body’s primary intracellular antioxidant.
The body continuously synthesizes glutathione, but intracellular levels decline with age, chronic oxidative stress, exposure to environmental toxins, smoking, excessive alcohol consumption, poor nutrition, and various chronic diseases. This decline has been associated with increased vulnerability to cellular damage, immune dysfunction, and accelerated cellular aging.
Exogenous glutathione administration aims to restore or elevate systemic levels beyond what endogenous synthesis can maintain under conditions of high oxidative demand.
Mechanism of Action
Free Radical Neutralization
GSH directly neutralizes reactive oxygen species (ROS) and reactive nitrogen species (RNS): superoxide, hydrogen peroxide, hydroxyl radicals, and peroxynitrite. It does so by donating a hydrogen atom from its thiol group (-SH) to form oxidized glutathione (GSSG), which is then regenerated back to GSH by the enzyme glutathione reductase (using NADPH as a cofactor).
This redox cycle represents the most potent known cellular antioxidant shield.
Antioxidant Recycling
GSH regenerates vitamin C (ascorbic acid) and vitamin E (alpha-tocopherol) from their oxidized forms, indirectly amplifying the entire dietary antioxidant system. This recycling function multiplies GSH’s impact far beyond its direct reactions.
Hepatic Detoxification — Phase II
In the liver, glutathione is an essential cofactor of glutathione-S-transferase (GST), the enzyme responsible for Phase II detoxification. Conjugation of GSH with xenobiotics (drugs, pesticides, heavy metals, carcinogenic metabolites) converts them into water-soluble compounds that can be excreted via bile or urine.
This mechanism explains the critical importance of GSH in liver function and the reason the liver has the highest concentration of glutathione in the body.
Immune System Modulation
GSH regulates T lymphocyte and NK (natural killer) cell function. T lymphocyte proliferation in response to antigens requires adequate intracellular GSH levels. Glutathione depletion impairs the adaptive immune response and promotes a chronic pro-inflammatory state.
Melanogenesis Inhibition (Aesthetic Effect)
At high and sustained doses, GSH inhibits the enzyme tyrosinase, shifting melanin production away from eumelanin (dark pigment) toward pheomelanin (light pigment). This effect, documented in Asian clinical studies, explains its off-label use as a skin-lightening agent — an application that is cosmetic, not therapeutic.
Why Subcutaneous Route?
Oral bioavailability of glutathione is less than 2%. The tripeptide is degraded in the gastrointestinal tract by peptidases before it can be absorbed intact. This makes oral GSH supplements have minimal systemic impact.
Routes that bypass intestinal first-pass degradation — intravenous (IV), intramuscular (IM), or subcutaneous (SC) — provide significantly greater systemic absorption. The SC route offers more gradual and sustained absorption than IV, which may be advantageous for maintaining stable plasma levels throughout the day.
Oral precursors as an alternative: N-acetylcysteine (NAC) and whey protein (a cysteine precursor) increase endogenous GSH synthesis by providing the rate-limiting cysteine. These have better oral bioavailability than direct GSH, but the physiological result is indirect.
Reported Protocol (SC Use)
Reconstitution: 600 mg in 3.0 mL bacteriostatic water → 200 mg/mL Equivalence: 1 U-100 unit = 2 mg (standard U-100 insulin syringe)
| Phase | Daily Dose | SC Volume | U-100 Units | Duration |
|---|---|---|---|---|
| Starter | 200 mg | 1.0 mL | 100 u | Weeks 1–2 |
| Maintenance | 400 mg | 2.0 mL | 200 u | Weeks 3–8 |
| Intensive | 600 mg | 3.0 mL | 300 u | Weeks 9–12 |
Route of administration: Subcutaneous, 1 injection per day (ideally AM fasted or post-exercise).
Volume note: Doses of 400–600 mg at 200 mg/mL involve volumes of 2–3 mL. For SC administration, this may require splitting across two injection sites or using larger-capacity syringes. Some protocols prefer reconstituting at a lower concentration (e.g., 100 mg/mL with 6.0 mL BAC water) for easier administration.
Storage
- Lyophilized (powder): ≤–20°C, protected from light.
- Reconstituted: 2–8°C (refrigerated), use within 28 days.
- Oxidation-sensitive: Reduced GSH progressively oxidizes in the presence of light, heat, or air. A reconstituted solution showing yellow discoloration or sulfur odor indicates oxidative degradation — discard immediately.
- Do not refreeze once reconstituted.
- Prepare in a clean environment and withdraw with aseptic technique.
Adverse Effects
Subcutaneous glutathione is generally well tolerated. Reported adverse effects include:
- Local injection site reactions: mild redness, itching, or induration — especially in the first few days or if large volumes are injected at a single point.
- Mild GI symptoms (less common): mild nausea reported by some users, possibly related to systemic absorption.
- Slightly sulfurous body odor: metabolism of sulfur-containing compounds derived from GSH.
- Potential interaction with chemotherapy: There is theoretical concern (and some experimental evidence) that very elevated glutathione levels may reduce the efficacy of chemotherapeutic agents that work by generating oxidative stress in tumor cells. Contraindicated in patients undergoing chemotherapy without explicit oncology supervision.
Documented Uses and Investigated Applications
| Area | Application | Evidence Level |
|---|---|---|
| Hepatic | Support in chronic hepatitis, fatty liver | Moderate (IV) |
| Neurological | Diabetic peripheral neuropathy | Limited (IV) |
| Dermatological | Hyperpigmentation, skin lightening | Moderate (oral/IV) |
| Oncology (adjuvant) | Reduction of cisplatin neuropathy | Moderate (IV) |
| Aging | Reduction of systemic oxidative stress | Emerging |
| Autoimmunity | Immune modulation in arthritis, lupus | Preliminary |
This content is for educational purposes only. Not medical advice. Always consult a healthcare professional.
Reported protocol (research reference)
| Vial sizes | 600 mg |
|---|---|
| Reported dose | 200 mg/day SC weeks 1-2 (starter). 400-600 mg/day weeks 3-12 (maintenance). Up to 600 mg/day intensive × 8-12 weeks. 1 U-100 unit = 2 mg at standard concentration (200 mg/mL). |
| Half-life | 2-3 hours IV; more gradual and sustained absorption via SC route. |
| FDA status | Not FDA approved |